Embracing cancer immunotherapy with manganese particles
Cellular Oncology · 2025-08 · 48 (4) · 899-920
DOI: 10.1007/s13402-025-01070-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cellular Oncology, online erschienen am 21.05.2025. Verfasst von Ali Moosavi Zenooz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran. Hauptthemen laut MEDLINE: Manganese, Immunotherapy, Neoplasms, Nanoparticles. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
- Students Research Committee, Ardabil University of Medical Sciences, Ardabil, Iran.
- Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran. Elham.im63@gmail.com.
- Department of Microbiology, Parasitology and Immunology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, 5166614711, Iran. Elham.im63@gmail.com.
Zitieren
APA
Moosavi Zenooz, A., Eterafi, M., Azarmi Giglou, S., & Safarzadeh, E. (2025). Embracing cancer immunotherapy with manganese particles. Cellular Oncology, 48(4), 899-920. https://doi.org/10.1007/s13402-025-01070-9
Vancouver
Moosavi Zenooz A, Eterafi M, Azarmi Giglou S, Safarzadeh E. Embracing cancer immunotherapy with manganese particles. Cellular Oncology. 2025;48(4):899-920. doi:10.1007/s13402-025-01070-9
BibTeX
@article{MoosaviZenooz2025,
author = {Moosavi Zenooz, Ali and Eterafi, Majid and Azarmi Giglou, Soheil and Safarzadeh, Elham},
title = {Embracing cancer immunotherapy with manganese particles},
journal = {Cellular Oncology},
year = {2025},
volume = {48},
number = {4},
pages = {899--920},
doi = {10.1007/s13402-025-01070-9}
}
EUVIMED